Hatteras Venture Partners, a Durham-based medical investment company, has raised $94 million for a venture fund.

This capital will contribute to the company’s goal of building a a $200 million venture fund, called HVP VI, to invest in health care and biotechnology companies.

The firm has over $550 million in capital commitments under management. It has invested in multiple North Carolina-based companies, including G1 Therapeutics, StrideBio and NeuroTronik.

“The pace and quality of our deal flow has grown tremendously during the past several years,” said Clay Thorp, cofounder and general partner of Hatteras Venture Partners, in a statement. “With HVP VI, we will continue to partner with innovative, driven entrepreneurs to launch and build world-class health care companies, many of which will be based upon leading-edge research stemming from the renowned academic centers in the southeastern U.S.”

Hatteras Venture Partners recently announced the addition of Ben Scruggs and Kseniya Simpson to the investment team. Scruggs and Simpson earned their doctorate degrees from Washington University in St. Louis and Yale University, respectively.

Hatteras also announced the promotions of Mike Dial and Jeff Terrell to partners. Both previously served as analysts.

Hatteras Venture Partners has a scientific advisory board made up of over 10 doctors.

The board is led by Herb Boyer, cofounder of biotechnology company Genentech. He earned his PhD at University of Pittsburgh and has over 40 years of experience in the medical investing field.